Simplified Chinese
scroll down
29
2024-09
In accordance with the Measures for Public Participation in Environmental Impact Assessment (Order No. 4 of the Ministry of Ecology and Environment), before submitting the environmental impact assessment documents to the competent environmental protection authority for approval, the project proponent shall publicly disclose the full text of the environmental impact report and the public participation statement. The Environmental Impact Report for the Nucleic Acid Vaccine R&D and Pilot-Scale Production Project, together with the public participation statement, is hereby made public. This project does not contain any information that, by law, should remain confidential; therefore, the disclosed version comprises the complete report. To access the public participation statement, please use the following link: https://pan.baidu.com/s/1dT1iSCN6bnA_MgRWd945GA.
13
2024-09
I. Methods for Obtaining the Draft for Public Comment 1. Paper Version: The public may review the document at Beijing Minhai Biotechnology Co., Ltd. 2. Electronic Version: Please refer to the attached file. II. Scope of the Public Subject to Comment The scope of this public consultation is limited to citizens, legal entities, and other organizations that are affected by or have a vested interest in the nucleic acid vaccine research and development and pilot‑scale production project. III. Online Link to the Public Comment Form During the period of public notice, if the public has any comments or views regarding the project’s construction or the environmental impact assessment, please complete the Public Comment Form and submit it to the project proponent. Link to download the Public Comment Form: http://www.mee.gov.cn/x
25
2024-08
I. Project Overview Project Name: Nucleic Acid Vaccine R&D and Pilot-Scale Production Facility Project Nature: Expansion Construction Site: No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing Total Investment: RMB 165.929 million Project Developer: Beijing Minhai Biotechnology Co., Ltd. Project Scope: The project will utilize the fourth floor of Building No. 1—R&D and Pilot-Scale Production—in Minhai Biotechnology’s Internationalized New‑Type Vaccine Industrial Base, along with the reserved workshop spaces on the fifth floor, to establish a pilot‑scale production facility for nucleic acid vaccine bulk solution and another for sub‑packaging. II. Environmental Impact Assessment Agency This time, the commission has been entrusted to Zhonghuan HuiBo (Beijing) International Engineering Technology Consulting Co., Ltd.
24
2024-05
Product Carbon Footprint Accounting Report – Beijing Minhai Biotechnology Co., Ltd.
Product Carbon Footprint Accounting Report – Beijing Minhai Biotechnology Co., Ltd.
23
2019-08
I. Statement In accordance with the provisions of the Environmental Protection Law of the People’s Republic of China, the Environmental Impact Assessment Law of the People’s Republic of China, the Regulations on the Administration of Environmental Protection for Construction Projects, and other relevant laws and regulations, information prior to the submission for approval of the environmental impact assessment report for this construction project is hereby made public. The project proponent shall be responsible for the accuracy of the information disclosed and will revise and refine the relevant contents of the environmental impact assessment report based on public feedback. II. Main Contents of the Pre-Approval Public Notice 1. Name of the construction project: R&D and Production Building Project (Third Floor) of Beijing Minhai Biotechnology Co., Ltd. 2. Name of the project proponent: Beijing Minhai Biotechnology Co., Ltd. 3. Environmental Impact Assessment Document…
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account
0
%